Vanguard Asset Management
SMMT icon

Vanguard Asset Management’s Summit Therapeutics SMMT Stock Holding History

Vanguard Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$417K Hold
28,611
– – ﹤0.01% 2254
2026
Q1 		$542K Buy
+28,611
New +$463K ﹤0.01% 2055

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Asset Management's SMMT Position: Q2 2026 in Review

Vanguard Asset Management held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 28,611 shares worth $417K. The position accounts for ﹤0.01% of the portfolio, ranked #2254.

Vanguard Asset Management first reported a position in SMMT in Q1 2026 and has held it in 2 quarters since. The position peaked at $542K in Q1 2026. 224 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Vanguard Asset Management held 28,611 shares of Summit Therapeutics worth $417K as of Q2 2026.
  • Vanguard Asset Management left its Summit Therapeutics share count unchanged in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2254 holding.
  • Vanguard Asset Management first reported a position in Summit Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Asset Management's Summit Therapeutics position peaked at $542K in Q1 2026.
  • 224 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.